-
1.发明公开METHODS AND COMPOSITIONS USEFUL IN GENERATING NON CANONICAL CD8+ T CELL RESPONSES 审中-公开用于产生非典型CD8 + T细胞应答的方法和组合物
公开(公告)号：EP3256595A1
公开(公告)日：2017-12-20
申请号：EP16749813.8
申请日：2016-02-10
申请人： Oregon Health & Science University , Fruh, Klaus , Picker, Louis , Hansen, Scott , Sacha, Jonah
发明人： FRUEH, Klaus , PICKER, Louis , HANSEN, Scott , SACHA, Jonah , MALOULI, Daniel
IPC分类号： C12N15/86 , C12N15/12 , C12N15/33 , C07K14/705 , C07K14/725 , C12N5/0783 , C12Q1/68 , A61K48/00 , A61P35/00
CPC分类号： C12N15/86 , A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/53 , A61K2039/57 , C12N9/0093 , C12N15/00 , C12N2710/16143 , C12N2740/15034 , C12Q1/68 , Y02A50/412
摘要： Methods of inducing a CD8+ T cell response to a heterologous antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.
-
2.发明公开
公开(公告)号：EP3200878A1
公开(公告)日：2017-08-09
申请号：EP15847978.2
申请日：2015-10-05
申请人： Los Alamos National Security, LLC , Oregon Health & Science University , Vir Biotechnology, Inc.
发明人： BRUENING, Eric , FRUEH, Klaus , PICKER, Louis , KORBER, Bette T.M. , THEILER, James , MARSHALL, Emily
CPC分类号： A61K39/12 , A61K39/21 , A61K2039/53 , A61K2039/70 , C12N2710/16143 , C12N2740/16034 , C12N2740/16234
摘要： Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
摘要翻译： 本文提供了使用EpiGraph方法确定的包含载体和群体遗传抗原的HIV-1疫苗。 还提供了包含载体，群体发生抗原和定制抗原的HIV-1疫苗。 还提供了设计和生产用于受试者的HIV-1疫苗的方法，包括使用EpiGraph方法产生的抗原氨基酸序列设计疫苗抗原以最优地覆盖地理区域内的多样性，并产生所述设计的疫苗抗原。 还提供了诱导效应记忆T细胞应答的方法，包括设计一个或多个EpiGraph氨基酸序列，产生包含一个或多个EpiGraph氨基酸序列的疫苗和载体，并将该疫苗给予受试者。 进一步提供了治疗受试者中的HIV-1的方法，其包括将有效量的所述HIV-1疫苗给予有需要的受试者。
-
公开(公告)号：EP3333265B1
公开(公告)日：2020-02-05
申请号：EP17197412.4
申请日：2011-05-16
IPC分类号： C12N15/869 , C12N15/33 , A61K39/29 , A61P31/12 , A61P35/00
-
4.发明公开
公开(公告)号：EP3529363A1
公开(公告)日：2019-08-28
申请号：EP17862978.8
申请日：2017-10-18
发明人： PICKER, Louis , HANSEN, Scott , FRUEH, Klaus , MALOULI, Daniel , NELSON, Jay , SACHA, Jonah , HANCOCK, Meaghan
-
公开(公告)号：EP2964769B1
公开(公告)日：2018-08-22
申请号：EP14759837.9
申请日：2014-03-05
发明人： PICKER, Louis , HANSEN, Scott , FRUEH, Klaus , MALOULI, Daniel
CPC分类号： C12N15/86 , A61K39/04 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/5256 , A61K2039/572 , C12N7/00 , C12N2710/16011 , C12N2710/16143 , C12N2740/15034
摘要： CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
-
6.发明公开CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING 审中-公开CYTOMEGALOVIRUS-VEKTOREN ZUR STEUERUNG EINES T-ZELLEN-TARGETINGS
公开(公告)号：EP2964769A1
公开(公告)日：2016-01-13
申请号：EP14759837.9
申请日：2014-03-05
发明人： PICKER, Louis , HANSEN, Scott , FRUEH, Klaus , MALOULI, Daniel
CPC分类号： C12N15/86 , A61K39/04 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/5256 , A61K2039/572 , C12N7/00 , C12N2710/16011 , C12N2710/16143 , C12N2740/15034
摘要： CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
摘要翻译： 本文公开了包含异源蛋白抗原，活性UL131蛋白（或其直系同源物），活性UL128蛋白（或其直系同源物），但其中CMV载体缺少活性UL130蛋白（或其直系同源物）的CMV载体， 。 本文还公开了包含：异源蛋白质抗原，活性UL131蛋白（或其直系同源物），活性UL130蛋白（或其直系同源物），但其中CMV载体缺少活性UL128蛋白的CMV载体。 进一步公开的是使用CMV载体产生特征为具有至少10％的CD8 + T细胞针对MHC II类所呈现的表位的免疫应答的方法。
-
公开(公告)号：EP4036239A1
公开(公告)日：2022-08-03
申请号：EP21205026.4
申请日：2016-02-10
发明人： FRUEH, Klaus , PICKER, Louis , HANSEN, Scott , SACHA, Jonah , MALOULI, Daniel
IPC分类号： C12N15/86 , C12N15/12 , C12N15/33 , C07K14/705 , C07K14/725 , C12N5/0783 , C12Q1/68 , A61K48/00 , A61P35/00
摘要： Methods of inducing a CD8+ T celi response to a heterologous antigen in which at least 10% of the CD8+ T cells are
MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 pro- teins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 pro- tein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.-
公开(公告)号：EP2569436B8
公开(公告)日：2019-10-30
申请号：EP11781407.9
申请日：2011-05-16
IPC分类号： C12N15/869 , C12N15/33 , A61K39/12 , A61P31/12 , A61P35/00
-
公开(公告)号：EP3377636A1
公开(公告)日：2018-09-26
申请号：EP16867316.8
申请日：2016-11-20
CPC分类号： A61K39/00 , A61K39/12 , A61K2039/5256 , A61K2039/552 , A61K2039/572 , C12N15/86 , C12N2710/16134 , C12N2710/16143 , C12N2740/15034
摘要： Disclosed herein are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an active UL128 protein and an active UL130 protein. Also disclosed are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an inactive UL128 protein and an inactive UL130 protein. Also disclosed are methods of generating an unconventional immune response using these vectors. Such an immune response is characterized by generation of a CD8+ T cell response that is predominantly restricted by MHC-II.
-
公开(公告)号：EP2569436B1
公开(公告)日：2017-11-29
申请号：EP11781407.9
申请日：2011-05-16
IPC分类号： C12N15/869 , C12N15/33 , A61K39/12 , A61P31/12 , A61P35/00
摘要： Described herein are recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens. The recombinant vectors elicit and maintain high level cellular and humoral immune responses specific for the heterologous antigen. The recombinant RhCMV and HCMV vectors may be used, for example, for the treatment or prevention of infectious disease or cancer. In some examples, the recombinant RhCMV or HCMV vectors may include deletions in genes encoding immunomodulatory proteins. In some examples, the recombinant RhCMV or HCMV vectors may be deficient or impaired in their ability to replicate within a cell, disseminate within the host or spread among hosts by including a deletion in one or more genes essential or augmenting for CMV replication, dissemination or spread.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.028 秒)
